<DOC>
	<DOCNO>NCT00130156</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety Bunazosin Valsartin compare Doxazosin Valsartin patient mild moderate essential hypertension accompany metabolic syndrome .</brief_summary>
	<brief_title>Effects Combination Therapy With Alpha-1 Blocker ( Bunazosin Doxazosin ) Treatment Patients With Mild Moderate Essential Hypertension</brief_title>
	<detailed_description>This clinical study comprise 1 2-week washout period , 5-week mono therapy period AngiotensinⅡantagonist , 8-week alpha blocker add-on treatment period . Total study period 15 week .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<mesh_term>Bunazosin</mesh_term>
	<criteria>Subjects mild moderate essential hypertension , follow criterion : 1 . Washout period ( Week 2 ) Male female subject age 20 80 year Systolic blood pressure ( SBP ) :140 mm Hg &lt; 180 mm Hg and/or diastolic blood pressure ( DBP ) :90 mm Hg &lt; 110 mm Hg Subjects give write informed consent prior participation trial undertake comply protocol 2 . Angiotensin II antagonist monotherapy period ( week 0 ) Subjects systolic blood pressure &gt; = 140 mm Hg &lt; 180 mm Hg and/or diastolic blood pressure &gt; = 90 mm Hg &lt; 110 mm Hg Presence 2 follow 4 risk factor Waist circumference : male &gt; 90 cm , female &gt; 80 cm Triglycerides &gt; = 150 mg/dl HDL cholesterol : male &lt; 40 mg/dl , female &lt; 50 mg/dl Fasting glucose &gt; = 110 mg/dl 3 . Angiotensin II antagonist addon Bunazosin Doxazosin treatment period ( Week 5 ) SBP &gt; =140 mm Hg decrease &lt; 10 % OR DBP &gt; =90 mm Hg decrease &lt; 10 % compare blood pressure entry Angiotensin II antagonist monotherapy period . Subjects follow condition eligible participation： ) Washout period ( Week 1 2 ) Subjects severe hypertension ( SBP &gt; =180 mm Hg DBP &gt; =110 mm Hg ) . Subjects proven suspect hypersensitivity quinazoline derivative Subjects history alcohol drug abuse . Subjects past present evidence cancer Subjects past history arterial fibrillation , heart failure ( LVEF &lt; 40 % ) , acute coronary syndrome , myocardial infarction , stroke severe arrhythmia . Subjects severely obese ( BMI &gt; 30 kg/m2 ) Women pregnant lactating suspect pregnant . Subjects previously participate clinical trial new unapproved substance within 12 week start washout period Subjects antihypertensive lipidlowering medication Inability return schedule visit comply aspect Protocol Subjects poorly control diabetes mellitus ( HbA1c &gt; 10 % ) Subjects concurrent serious hepatic renal disorder ( define AST and/or ALT &gt; 3 time upper normal limit Cr &gt; 2mg/dl ) . Subjects , opinion investigator , poor medical candidate pose risk therapy investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Blood pressure</keyword>
	<keyword>SBP</keyword>
	<keyword>DBP</keyword>
</DOC>